|Bid||0.00 x 1800|
|Ask||0.00 x 900|
|Day's Range||76.53 - 77.72|
|52 Week Range||74.13 - 147.17|
|PE Ratio (TTM)||21.34|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Wall Street was split Wednesday on Celgene as one sell-side analyst downgraded the stock saying it "has tilted to greater risk" while another upgraded shares.
It's been two years since David's picked a batch of stocks made to thrive in a global society that's ever more focused on the life of the mind.
Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to Outperform and cut the price target from $121 to $102. By Bernstein’s assessment, Celgene’s current discounted cash flow reflects the worst possible outcome for the Revlimid trial — a result that could push the launch to April 2020. Toung is less optimistic about Revlimid’s legal issues, which could increase share volatility with an adverse ruling.
Celgene Corp. sell-side analysts can’t agree on what’s next for the company with shares hovering near a four-year low. Argus analyst David Toung moved to the sidelines on a risk-reward that has “tilted to greater risk” given an over-reliance on one of the world’s biggest brand-name cancer treatments, Revlimid. Shares tumbled on Monday to a four-year low after a news article about the departure of its former business development head, George Golumbeski, added gasoline to the fire of concerns for the drugmaker.
The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.
Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.
After years of growth, Celgene Corporation (NASDAQ:CELG) has spent the past eight months suffering from ever-weakening price action. In fact and with shares of Celgene now off a full 50% from 2017’s all-time-highs following Monday’s 4.70% price drop, you could say bears have been acting with barely any hesitation in CELG stock. The latest ‘disappointment’ in shares of Celgene, judging by Monday’s price reaction, is a report that Celgene’s top dog of business development discreetly retired over a month ago.
Celgene Corporation (NASDAQ: CELG ) — which is recently very much in the news, although for dubious reasons — has struck a partnership with Germany's Evotec AG (ADR) (OTC: EVTCY ), which partners with ...
First we gauge the performance of David’s recommendations. Then, he interviews Middleby Corp.'s remarkable leader, Selim Bassoul.
SCYNEXIS (SCYX) witnessed a 28% rise in its stock price in the week ended May 18. On May 18, SCYNEXIS stock closed at $1.63, which is ~14.4% growth from its previous close of $1.43 on May 17. SCYNEXIS stock rose ~27% over the last month. SCYNEXIS is a biotechnology company focused on the development of innovative therapies for the treatment of patients with difficult-to-treat and life-threatening infections.
The S&P 500’s top losses on May 21 were: Fifth Third Bancorp (FITB) declined 7.9%. Celgene (CELG) declined 4.7%. Symantec (SYMC) declined 2.7%. Allergan (AGN) declined 2.7%. Campbell Soup (CPB) declined 2.3%. Fifth Third Bancorp
U.S. biotechnology company Celgene Corp. ( CELG) has entered into a long-term strategic drug discovery and development partnership with Hamburg, Germany-based Evotec AG. In a brief statement, Evotec said it will receive an upfront payment of $65 million for its role in the partnership, as well as the potential to earn “significant milestone payments” and “tiered royalties” on each licensed program. Celgene and Evotec have already partnered up before.
Celgene plunged to another four-year low Monday on a report that an executive in charge of business development quietly retired in mid-April.
U.S. stocks jumped higher Monday on news that trade tensions between China and the U.S. are cooling off. Can stocks continue higher this week? Here are our top stock trades for Tuesday. Top Stock Trades for Tomorrow #1: Celgene (CELG)
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...
The Food and Drug Administration (FDA) announced a shame list of companies that try to block generic drugs in order to ramp up profits.
On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.
BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.
TRENTON, N.J. (AP) — U.S. drug regulators are publicizing information on brand-name drugmakers that use what government officials call "gaming tactics" to block cheaper copycat versions.
Celgene toppled to a four-year low Thursday after it appeared on a list from the FDA attempting to "shame" drugmakers working to block generic competition.
Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.